TODENTJ-25-03-2019_TODENTJ-5-163 1553505287 Bentham Open doi@benthamopen.net Bentham Open The Open Dentistry Journal TODENTJ 1874-2106 10 21 2011 5 1 Nafiseh Soolari Ahmad Soolari Background and Objective: Many clinicians will not treat patients presenting with bisphosphonate-related osteonecrosis of the jaw following long-term use of bisphosphonates because of the lack of predictable outcomes. Materical and Methods: The patient presented with pain from a nonhealing lesion in the posterior maxilla following extraction of the maxillary right third molar. The lesion had not responded to any conventional dental treatment. The patient had suffered from breast cancer, and her treatment included several years of therapy with Zometa (zoledronic acid), a bisphosphonate. Results: The patient stopped taking Zometa and commenced rinsing with phosphate buffer–stabilized 0.1% chlorine dioxide–containing mouthwash. After 5 months, changes in the morphology of the lesion were noted and the soft tissue had closed over the open wound. Conclusion: Cessation of bisphosphonate therapy and usage of a phosphate buffer–stabilized 0.1% chlorine dioxide–containing mouthwash lessened the patient’s pain and resulted in closure of the soft tissue lesion. 10 21 2011 163 167 TODENTJ-5-163 1 10.2174/crossmark_policy opendentistryjournal.com benthamopen.com true Peer Reviewed Single blind Checked with iThenticate 2011-6-29 2011-9-19 2011-9-21 2011-10-21 http://creativecommons.org/licenses/by-nc/3.0/ 10.2174/1874210601105010163 1553505287 https://opendentistryjournal.com/VOLUME/5/PAGE/163/ https://opendentistryjournal.com/contents/volumes/V5/TODENTJ-5-163/TODENTJ-5-163.pdf https://opendentistryjournal.com/contents/volumes/V5/TODENTJ-5-163/TODENTJ-5-163.pdf https://opendentistryjournal.com/contents/volumes/V5/TODENTJ-5-163/TODENTJ-5-163.pdf https://opendentistryjournal.com/contents/volumes/V5/TODENTJ-5-163/TODENTJ-5-163.pdf https://opendentistryjournal.com/contents/volumes/V5/TODENTJ-5-163/TODENTJ-5-163.pdf https://opendentistryjournal.com/contents/volumes/V5/TODENTJ-5-163/TODENTJ-5-163.pdf https://opendentistryjournal.com/contents/volumes/V5/TODENTJ-5-163/TODENTJ-5-163.pdf https://opendentistryjournal.com/contents/volumes/V5/TODENTJ-5-163/TODENTJ-5-163.xml Breastcancer.org: Breast cancer, 2010 Available: http://www.breastcancer.org [Accessed 2011]; U.S. National Library of Medicine. Genetics home reference: Breast cancer 2007 Available: http://ghr.nlm.nih.gov/condition=breastcancer [Accessed 2011]; Hum Reprod 10 281 2004 ESHRE Capri Workshop Group. Hormones and breast cancer Hum Reprod 2004; 10 (4) : 281-3. Available: http://www.cancer.gov/newscenter/pressreleases/STA-RresultsApr172006 2006 National Cancer Institute. Results of the study of tamoxifen and raloxifene (STAR) released: osteoporosis drug raloxifene shown to be as effective as tamoxifen in preventing invasive breast cancer Available: http://www.cancer.gov/newscenter/pressreleases/STA-RresultsApr172006 2006 [Accessed 2011]; J Oral Pathol Med Bagan JV 34 120 2005 Bagan JV. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases J Oral Pathol Med 2005; 34 (2) : 120-3. J Clin Oncol Migliorati CA 21 4253 2003 Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis J Clin Oncol 2003; 21 (22) : 4253-. J Oral Maxillofac Surg Ruggiero SL 62 527 2004 Ruggiero SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases J Oral Maxillofac Surg 2004; 62 (5) : 527-34. J Oncol Pract Ruggiero SL 2 7 2006 Ruggiero SL. Practical guidelines for the prevention, diagnosis and treatment of osteonecrosis of the jaw in patients with cancer J Oncol Pract 2006; 2 (1) : 7-14. J Oral Maxillofac Surg Marx RE 61 1115 2003 Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic J Oral Maxillofac Surg 2003; 61 (9) : 1115-7. J Oral Maxillofac Surg Marx RE 63 1567 2005 Marx RE. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment J Oral Maxillofac Surg 2005; 63 (11) : 1567-75. J Am Dent Assoc Migliorati CA 136 1658 2005 Migliorati CA. Managing the care of patients with bisphosphonate-associated osteonecrosis: an american academy of oral medicine position paper J Am Dent Assoc 2005; 136 (12) : 1658-68. Lancet Oncol Migliorati CA 7 508 2006 Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment Lancet Oncol 2006; 7 (6) : 508-14. N Engl J Med Woo SB 353 99 2005 Woo SB. Osteonecrosis of the jaw and bisphosphonates N Engl J Med 2005; 353 (1) : 99-102. Clin Breast Cancer Gralow J 5 S54 2005 Gralow J. Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer Clin Breast Cancer 2005; 5 (Suppl 2) : S54-62. Mund Kiefer Gesichtschir Piesold JU 10 287 2006 Piesold JU, Al-Nawas B, Grötz KA. Osteonecrosis of the jaws by long term therapy with bisphosphonates Mund Kiefer Gesichtschir 2006; 10 (5) : 287-300. J Clin Pharmacol Chen T 42 1228 2002 Chen T, Berenson J, Vescio R, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases J Clin Pharmacol 2002; 42 : 1228-36. Obstet Gynecol Thorpe J 106 402 2005 Thorpe J. Alendronate (Fosamax) and risedronate (Actonel) revisited Obstet Gynecol 2005; 106 (2) : 402-. N Engl J Med Bilezikian JP 355 2278 2006 Bilezikian JP. Osteonecrosis of the jaw: do bisphosphonates pose a risk? N Engl J Med 2006; 355 (22) : 2278-81. Bone Dannemann C 40 828 2007 Dannemann C, Grätz KW, Riener MO, Zwahlen RA. Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder Bone 2007; 40 (4) : 828-34. Am J Hematol Zarychanski R 81 73 2006 Zarychanski R. Osteonecrosis of the jaw associated with pamidronate therapy Am J Hematol 2006; 81 (1) : 73-5. Crit Rev Oncol Hema-tol Weitzman R 62 148 2007 Weitzman R, Sauter N, Eriksen E, et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients Crit Rev Oncol Hema-tol 2007; 62 (2) : 148-52. Med Clin (Barc) Calvo-Villas JM 127 576 2006 Calvo-Villas JM. Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid Med Clin (Barc) 2006; 127 (15) : 576-9. Br J Haematol Zervas K 134 620 2006 Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients Br J Haematol 2006; 134 (6) : 620-3. J Oral Maxillofac Surg Mavrokokki T 65 415 2007 Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia J Oral Maxillofac Surg 2007; 65 (3) : 415-23. J Clin Oncol Bamias A 23 8580 2005 Bamias A. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors J Clin Oncol 2005; 23 (34) : 8580-7. Inside Dent Rose L 3 44 2007 Rose L, Ruggiero S, Silverstein L. When can patients who are being treated with oral and IV bisphosphonates receive periodontal, implant, and/or oral surgical care? Inside Dent 2007; 3 (9) : 44-5. IBMS BoneKey Somerman MJ 3 12 2006 Somerman MJ, McCauley LK. Bisphosphonates: sacrificing the jaw to save the skeleton? IBMS BoneKey 2006; 3 (9) : 12-5. Ann Pharmacother Krueger CD 41 276 2007 Krueger CD, West PM, Sargent M, Lodolce AE, Pickard AS. Bisphosphonate-induced osteonecrosis of the jaw Ann Pharmacother 2007; 41 (2) : 276-84. Oral Oncol Bagan JV 42 327 2006 Bagan JV, Jimenez Y, Murillo J, et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. study of 20 cases Oral Oncol 2006; 42 (3) : 327-9. Ann Intern Med Woo SB 44 753 2006 Woo SB, Hellstein JW, Kalmar JR. Narrative review: bisphosphonates and osteonecrosis of the jaws Ann Intern Med 2006; 44 (10) : 753-61. Laryngoscope Farrugia MC 116 115 2006 Farrugia MC, Summerlin DJ, Krowiak E, et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates Laryngoscope 2006; 116 : 115-20. J Orofac Pain Wang H 78 584 2007 Wang H, Weber D, McCauley LK. Effect of long-term oral bisphosphonate on implant wound healing: literature review and a case report J Orofac Pain 2007; 78 : 584-94. J Clin Endocrinol Metab Khamaisi M 92 1172 2007 Khamaisi M, Regev E, Yarom N, et al. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis J Clin Endocrinol Metab 2007; 92 (3) : 1172-5. Leukemia Corso A 21 1545 2007 Corso A, Varettoni M, Zappasodi P, et al. Different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma Leukemia 2007; 21 (7) : 1545-8. J Am Dent Assoc Adornato MC 138 971 2007 Adornato MC, Morcos I, Rozanski J. The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone re-section and autologous platelet-derived growth factors J Am Dent Assoc 2007; 138 (7) : 971-7. American Academy of Periodontology. AAP Statement on Bisphosphonates, 2010 Available: www.perio.org/resources-products/bisphosphonates.htm [Accessed 20 March 2011]; J Am Dent Assoc Sedghizadeh PP 140 1259 2009 Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW. Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy J Am Dent Assoc 2009; 140 (10) : 1259-65. J Clin Dent Grootvelt M 12 67 2001 Grootvelt M, Silwood C, Gill D, Lynch E. Evidence for the microbicidal activity of a chlorine dioxide-containing oral rinse formulation in vivo J Clin Dent 2001; 12 (3) : 67-70. Trials Shinada K 11 14 2010 Shinada K, Ueno M, Konishi C, et al. Effects of a mouthwash with chlorine dioxide on oral malodor and salivary bacteria: a randomized placebo-controlled 7-day trial Trials 2010; 11 : 14. Translation Biomed Soolari E 1 7 2010 Soolari E, Soolari A, Soolari A. Phosphate buffer-stabilized 0.1% chlorine dioxide-containing mouth wash facilitate sequestration of bisphosphonate related osteonecrosis of jaw (BRONJ) lesion from a patient who presented with osteonecrosis of the jaw and a history of intravenous bisphosphonate use: case report Translation Biomed 2010; 1 (1) : 7. Dent Today Marder MZ 27 99 2008 Marder MZ, Marder RW. Bisphosphonate-associated osteonecrosis experiences in a private practice Dent Today 2008; 27 (10) : 99-103.